No way! But... [Design Issues]

posted by wienui  – Germany, Oman, 2019-12-07 04:01 (499 d 13:41 ago) – Posting: # 20955
Views: 3,927

(edited by wienui on 2019-12-07 06:47)

Dear all,

» So here two answers - theoretically there is no problem to use all data, but regulatory authorities can bann you for it. (IMHO)

I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?

Best regards,
Osama

Cheers,
Osama

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 11 (0 registered, 11 guests [including 2 identified bots]).
Forum time: Monday 18:43 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5